Detalhe da pesquisa
1.
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program.
Mult Scler J Exp Transl Clin
; 10(2): 20552173241238632, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38784791
2.
Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon ß-1a users.
Neurodegener Dis Manag
; 13(3): 151-159, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779318
3.
Analysis of Pregnancy Outcomes Following Exposure to Intramuscular Interferon Beta-1a: The AVONEX® Pregnancy Exposure Registry.
Drugs Real World Outcomes
; 10(4): 503-511, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37737962
4.
Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey.
Mult Scler J Exp Transl Clin
; 9(3): 20552173231198588, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37720692
5.
Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients.
Mult Scler Relat Disord
; 60: 103700, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263702
6.
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.
Adv Ther
; 38(7): 3550-3588, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34075554
7.
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord
; 51: 102935, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882426
8.
Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.
Lancet Neurol
; 17(10): 870-884, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30143361
9.
Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.
Adv Ther
; 39(1): 822-830, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34792786